NHS Scotland's Golden Jubilee National Hospital Uses MicroStrategy to Improve Operations and Enhance Patient Care
First Hospital Light Fixture to Kill Bacteria Safely and Continuously Becomes Commercially Available in U.S. and Canada
Research and Markets: United Kingdom Medical Insurance Report 2015
Mylan Launches First Bioequivalent Alternative to Combination Asthma Therapy Seretide® Evohaler® (Salmeterol Xinafoate/Fluticasone Propionate) Under the Brand Name Sirdupla™ in the UK
Pacritinib Phase 3 Study Shows Positive Results In Patient Reported Outcomes Measuring Quality Of Life In Patients With Myelofibrosis
CTI BioPharma And Baxter Announce Patient-Reported Outcomes (PROs) From Pacritinib Phase 3 In Patients With Myelofibrosis To Be Presented In Late-Breaking Session At EHA
New Synexus Board Gears up for Expansion Through Organic Growth and Acquisition
Omicia Wins UK's 100,000 Genomes Project as Clinical Interpretation Provider
These closed-end funds were unstoppable in early 2015; plus, did the first IPO of 2015 usher in a new era for CEF shareholders?
Dan Plettner invests and receives income for securities research, including “buy-side” research. Dan licenses his own real time trading data to Covestor Ltd. (“Covestor”), frequently including positions discussed in his Morningstar Contributions. Covestor is a Registered Investment Advisor that ...